Haemophilia B+ with Inhibitor

Thromb Haemost 1988; 59(02): 340
DOI: 10.1055/s-0038-1642788

Letters to the Editor

Schattauer GmbH Stuttgart

Authors

M Ludwig

¹Institute of Radiation Biology, Sigmund-Freud-Straβe, 5300 Bonn 1, West Germany
R Schwaab

¹Institute of Radiation Biology, Sigmund-Freud-Straβe, 5300 Bonn 1, West Germany
K Olek

¹Institute of Radiation Biology, Sigmund-Freud-Straβe, 5300 Bonn 1, West Germany
H H Brackmann

²Institute of Experimental Haematology and Blood Transfusion, Sigmund-Freud-Straβe, 5300 Bonn 1, West Germany
H Egli

²Institute of Experimental Haematology and Blood Transfusion, Sigmund-Freud-Straβe, 5300 Bonn 1, West Germany

References
1 Giannelli F, Choo KH, Rees DJ G, Boyd Y, Rizza CR, Brownlee GG. Gene deletions in patients with haemophilia B and anti-factor IXantibodies. Nature 1983; 303: 181-2
2 Matthews RJ, Anson DS, Peake IR, Bloom AL. Heterogeneity of thefactor IX locus in nine hemophilia B inhibitor patients. J Clin Invest 1987; 79: 746-753
3 Brackmann HH, Egli H. Treatment of hemophilia patients withinhibitors. In: Haemophilia. Seligsohn U, Rimon A, Horoszowski H. (eds) Castle House Publications Ltd; London: 1984. pp 113-119
4 Jaye M, De La Salle H, Schamber F, Balland A, Kohli V, Findeli A, Tolstoshev P, Lecocq JP. Isolation of a human anti-haemophilic factorIX cDNA clone using a unique 52-base synthetic oligonucleotide probededuced from the amino acid sequence of bovine factor IX. NucleicAcid Res 1983; 11: 2325-2335